S&P Futures
4,062.75 +58.00 (+1.45%) Dow Futures
32,490.00 +331.00 (+1.03%) Nasdaq Futures
12,492.00 +247.25 (+2.02%) Russell 2000 Futures
1,810.00 +27.60 (+1.55%) Crude Oil
114.71 +0.51 (+0.45%) Gold
1,826.30 +12.30 (+0.68%)
Ultragenyx Pharmaceutical Inc. (RARE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 51.47 |
| Open | 51.36 |
| Bid | 22.04 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 50.90 - 55.83 |
| 52 Week Range | 49.24 - 115.25 |
| Volume | |
| Avg. Volume | 462,526 |
| Market Cap | 3.767B |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.32 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 128.81 |
- GlobeNewswire
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
Oral presentations include longer term durability data from DTX301 and DTX401, and manufacturing data on the Pinnacle PCL™ (AAV vector Producer Cell Line) platform and technologyNOVATO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its investigational gene t
- Zacks
Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
- Zacks
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
